For patients 65+, Fluzone High-Dose vaccine is the only senior influenza vaccine with superior efficacy compared with Fluzone vaccine.1,2 Fluzone High-Dose vaccine delivers 4X the amount of antigen of Fluzone vaccine.1 Since 2009, more than 90 million doses have been sold in the United States.3


Proven Efficacy

According to the randomized, controlled, head-to-head trial conducted in more than 30,000 seniors 65 years of age and older, over 2 flu seasons, Fluzone High-Dose vaccine provided1:

Primary Endpoint
24.2%
Better Protection
from Influenza
compared with Fluzone vaccine1,2
Primary endpoint of the study was the occurrence of laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine components.
Secondary Endpoint
51.1%
Better Protection
from Influenza
compared with Fluzone vaccine1,2
A secondary endpoint of the study was the occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention-defined influenza-like illness.

Proven in a randomized controlled trial to prevent more cases of influenza in adults 65+ compared with Fluzone vaccine1,2

  • Results published in the New England Journal of Medicine
  • The only senior influenza vaccine with superior efficacy compared with Fluzone vaccine1,2,a
    • More than 30,000 subjects across 2 flu seasons: 2011-2012 and 2012-20131,a
    • Across multiple strains of influenza: A (H1N1), A (H3N2), and B2
    • With vaccine components that were well matched or not well matched to the circulating strains1,2
  • Since 2009, more than 90 million doses of Fluzone High-Dose vaccine have been sold in the United States3
  • 4X the amount of antigen of Fluzone vaccine1,2
  • Nearly 70% of adults 65+ who were vaccinated against the flu during the 2016-2017 flu season received Fluzone High-Dose vaccine4

aPer-protocol analysis set for efficacy assessments.1

Safety Information

Safety Demonstrated

  • In adults 65 years of age and older (N=3,832)1
  • In a multicenter, randomized, double-blind, controlled trial1
  • Subjects were randomized 2:1 to receive Fluzone High-Dose vaccine vs Fluzone vaccine1

Fluzone High-Dose Vaccine compared with Fluzone Vaccine in adults 65+1


Fluzone High-Dose Vaccine Injection-Site and System Reactions Fluzone High-Dose Vaccine Injection-Site and System Reactions